We could not find any results for:
Make sure your spelling is correct or try broadening your search.
The current CRL market cap is 11.15B. The company's latest EPS is USD 9.2430 and P/E is 23.49.
Quarter End | Apr 2023 | Jul 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Revenue | 1.03B | 1.06B | 1.03B | 1.01B | 1.01B |
Operating Income | 167.89M | 163.88M | 151.5M | 132.92M | 133.94M |
Net Income | 103.13M | 97.02M | 87.39M | 187.08M | 67.33M |
Year End 30 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Revenue | 2.62B | 2.92B | 3.54B | 3.98B | 4.13B |
Operating Income | 351.15M | 432.73M | 589.86M | 650.98M | 617.26M |
Net Income | 252.02M | 364.3M | 390.98M | 486.23M | 474.62M |
Quarter End | Apr 2023 | Jul 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Assets | 7.7B | 7.77B | 7.61B | 8.2B | 8.15B |
Total Liabilities | 4.54B | 4.47B | 4.26B | 4.54B | 4.45B |
Total Equity | 3.11B | 3.26B | 3.31B | 3.6B | 3.65B |
Year End 30 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Assets | 4.69B | 5.49B | 7.02B | 7.6B | 8.2B |
Total Liabilities | 3.03B | 3.35B | 4.43B | 4.58B | 4.54B |
Total Equity | 1.64B | 2.12B | 2.54B | 2.98B | 3.6B |
Quarter End | Apr 2023 | Jul 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Operating | 109.38M | 257.51M | 462.96M | 683.9M | 129.89M |
Investing | -168.62M | -245.23M | -324.78M | -563.16M | -85.79M |
Financing | 25.24M | -46.22M | -209.09M | -85.52M | 18.35M |
Year End 30 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Operating | 480.94M | 546.58M | 760.8M | 619.64M | 683.9M |
Investing | -681.5M | -601.54M | -1.44B | -607.92M | -563.16M |
Financing | 231.94M | 47.25M | 672.6M | -42.4M | -85.52M |
Market Cap | 11.15B |
Price to Earnings Ratio | 23.49 |
Price to Sales Ratio | 2.7 |
Price to Cash Ratio | 40.29 |
Price to Book Ratio | 3.05 |
Dividend Yield | - |
Shares Outstanding | 51.35M |
Average Volume (1 week) | 495.34k |
Average Volume (1 Month) | 559.13k |
52 Week Change | 8.89% |
52 Week High | 275.00 |
52 Week Low | 161.65 |
Spread (Intraday) | 3.16 (1.45%) |
Company Name | Charles River Laboratories International Inc |
Address |
251 little falls drive wilmington, delaware 19808 |
Website | https://www.criver.com |
Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions